Magnetic resonance and optical imaging probes for NMDA receptors on the cell surface of neurons : synthesis and evaluation in cellulo. by Sim,  N. et al.
Durham Research Online
Deposited in DRO:
19 November 2014
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Sim, N. and Pal, R. and Parker, D. and Engelmann, J. and Mishra, A. and Gottschalk, S. (2014) 'Magnetic
resonance and optical imaging probes for NMDA receptors on the cell surface of neurons : synthesis and
evaluation in cellulo.', Organic biomolecular chemistry., 12 (46). pp. 9389-9404.
Further information on publisher's website:
http://dx.doi.org/10.1039/C4OB01848F
Publisher's copyright statement:
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
OBC	  	  2014	  	  
	   1	  
Magnetic resonance and optical imaging probes for NMDA receptors 
on the cell surface of neurons: synthesis and evaluation in cellulo   
 
Neil Sima, Robert Pala, David Parker, *a Joern Engelmann b, Anurag Mishra* a,c and Sven 
Gottschalkb,c 
 
a Department of Chemistry, Durham University, South Road, Durham DH1 3LE, UK 
b High Field MR Centre, Max Planck Institute for Biological Cybernetics, Spemannstrasse 41,   
Tuebingen, D-72076, Germany.  
c Institute for Biological and Medical Imaging, Helmholtz Center, Munich, Neuherberg, D-
85764, Germany. 
 
email: david.parker@dur.ac.uk;	  anurag.mishra@helmholtz-muenchen.de 
 
A second generation of N-methyl-D-aspartate (NMDA) receptor-targeted MRI contrast agents 
has been synthesised and evaluated in cellulo, based on established bicyclic NMDA receptor 
antagonists. Their use as responsive MR imaging probes has been evaluated in suspensions of 
NSC-34 cells, and one agent exhibited significant enhancements in measured longitudinal and 
transverse water proton relaxation rates (19 and 38% respectively; 3T, 298K). A biotin 
derivative of the lead compound was prepared and the specificity and reversibility of binding 
to the NMDA cell surface receptors demonstrated using confocal laser scanning microscopy. 
Competitive and reversible binding of glutamate to the receptors was also visualised, 
suggesting that the receptor-targeted approach may allow MRI to be used to monitor neuronal 
events associated with modulation of local glutamate concentrations. 
 
Introduction   
Receptors for N-methyl-D-aspartate (NMDA) are found on the surface of neurons (e.g. 
astrocytes) and constitute part of the ligand-gated ionotropic family of glutamate receptor 
proteins.1 These receptors play a key role in excitatory neurotransmission and in memory and 
learning. Many central nervous system (CNS) disorders have been related to the mis-
regulation or over-stimulation of NMDA receptors including epilepsy, ischemia, Parkinson’s 
and Alzheimer’s diseases. 2-4   Selective antagonists of the NMDA receptors (NMDAR) have 
also been studied, exploring their potential as imaging or therapeutic agents for these and 
related CNS disorders. 5,6    
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One of the goals of molecular imaging is to provide more detailed spatiotemporal information 
on the chemical processes occurring in the brain that are associated with neurotransmission 
and its relationship to learning, cognitive behaviour and disease status and progression. The 
utility of MRI is improved by the use of contrast agents, especially those that enhance 
specificity and sensitivity by targeting certain regions of interest, or that allow the monitoring 
of changes in chemical composition as a function of neural activity.  This rationale has driven 
the recent development of contrast agents that selectively target the various glutamate 
receptors that are found on the cell surface of astrocytes in high abundance. 7,8,9 Such 
responsive contrast agents must be able to bind selectively and reversibly to the receptor, so 
that changes in local contrast agent levels can be modulated following the glutamate bursts 
that periodically occur following a stimulus. Given that release of glutamate from a pre-
synaptic cell takes place over a period of milliseconds and should displace the contrast agent 
from the cell surface receptor, MRI may be able to monitor the restoration to equilibrium that 
occurs over a period of a second or two.10 As the glutamate levels drop and the contrast agent 
competes in binding to the receptor, glutamate is displaced, leading to local signal intensity 
enhancement once more. Such a perturbational approach requires that the contrast agents bind 
reversibly and with relatively high affinity to the target site, with minimal non-specific 
binding.  
For these reasons, we have set out to examine conjugates of gadolinium contrast agents with 
established competitive antagonists for glutamate receptors. When bound to the receptor site, 
the local rotational dynamics and second sphere of hydration around the gadolinium moiety 
are perturbed leading to relaxivity enhancement and increased contrast. In our initial work 
with NMDA receptor targeted gadolinium conjugates, we reported the synthesis and 
behaviour of competitive NMDAR antagonists based on a 3,4-diamino-3-cyclobutene-1,2-
dione  developed by Kinney.11a The NMDA receptor is a tetrameric complex, most commonly 
built up from alternating GluN1 and GluN2 subunits. Based on the work of Kinney 11b, these 
receptor binding moieties are a class of competitive antagonists. Therefore, they must bind at 
the GluN2 subunit where the glutamate binding site is located. However, the GluN2 subunit 
can be one of four genetic products (GluN2A-D) and the relative expression levels of each 
can vary between each receptor. In initial work13, immunofluorescence staining experiments 
were undertaken to establish the presence of the GluN2B subunit.  
The targeting moieties based on the competitive antagonist moiety were conjugated to a 
modified Gd-DOTA complex that possesses a single fast-exchanging water molecule, e.g. 
[Gd.La-d], Scheme 1.  When water exchange at the Gd centre is fast (typically of the order of 
107s-1 at 298 K), then the relaxivity, (the increment of the water proton relaxation rate per unit 
complex concentration) in the low to mid-field range (1 to 3 T), is dominated by rotational 
dynamics and hence is more sensitive to receptor binding.12 Initial studies in cell suspensions 
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of the NSC-34 cell line showed relaxation enhancements of up to 75% on cell surface binding 
versus controls lacking the NMDA receptors.13 The conjugates were non-toxic, as revealed by 
standard IC50 studies using an MTT assay that assesses perturbation of mitochondrial redox 
status, consistent with evidence from optical microscopy studies that revealed no evidence for 
internalization of the conjugate. Furthermore, the confocal microscopy studies established 
both the specificity and the reversibility of probe binding, in the absence and presence of 
added glutamate.13 
 
   
     Scheme 1 
 
Here, we report the synthesis and evaluation of an additional series of complexes constituting a second-
generation, [Gd.L1-L6] (Scheme 1) in which the monocyclic antagonist group is replaced by a bicyclic 
moiety, for which receptor binding affinities were established to be about an order of magnitude 
higher, in the original small molecule work. 11b  The nature of the spacing chain differs in each case and 
four examples with shorter linkages (Gd.L1-Gd.L4) were examined together with two analogues 
(Gd.L5, Gd.L6) in which the spacing chain was longer.  The rationale behind this selection of targets 
was that the further away the targeting vector was from the paramagnetic Gd3+ centre, the less likely 
that receptor binding would be compromised. However, the longer the chain the less motional coupling 
will occur between the gadolinium moiety and the slowly tumbling macromolecule, comparing free 
and receptor bound complexes and hence the smaller may be any relaxivity enhancement.   
In addition, we have examined the behaviour of the biotin conjugate, [Gd.L7], in which the biotin 
moiety allows selective tagging to fluorescently labelled avidin conjugates to allow visualization of the 
avidin-biotin probe conjugate using confocal microscopy.    
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Results and Discussion    
Synthesis of the ligands and complexes  
The synthesis of the required bicyclic antagonist moieties followed methods adapted from the 
work of Kinney 11b. Orthogonal protection of 1,3-diamino-propan-2-ol was achieved in high 
yield following stepwise Boc and Z protection steps.14a Subsequent mesylation of the free 
alcohol, followed by substitution with NaN3 in DMF afforded the azide, 3 (Scheme 2). The 
azide group served as a ‘masked’ amine, which was transformed to a primary amine group in 
the final step of the synthesis. A reagent for selective removal of the CBz protecting group 
from 3 was required. This ruled out the use of standard deprotection methods, such as 
hydrogenation over a palladium catalyst, as this would also reduce the azide group. Instead, 
Ba(OH)2 in refluxing aqueous glyme was used, and gave the free amine, 4,  in good yield.14b 
N-Alkylation with, for example, diethyl-(2-bromo)ethyl phosphonate in the presence of 
Na2CO3 gave the mono-substituted amine, 7,  in modest yield, which was used in a Michael 
addition-elimination reaction with diethoxy-3-cyclobutene-1,2-dione. The phosphonate ester 
11 was obtained as a pair of rotamers in a 1:1.2 ratio as deduced by 31P NMR spectroscopy. 
Cyclisation was achieved in high yield after selective hydrolysis of the Boc protecting group, 
followed by heating the free amine in ethanol in the presence of a tertiary amine. By studying 
the 1H NMR spectrum of the cyclised azide, 15, it was possible to deduce that the 
conformation adopted by this and related bicyclic intermediates involved selective population 
of a twist-chair isomer (ESI). In a similar manner, compounds 13, 14 and 16 were prepared.  
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Scheme 2. Synthesis of the competitive antagonist moieties (adapted from reference 11b) 	  	  	  
With the azide in hand, mild, selective reduction to unmask the primary amine functionality 
was accomplished using a standard Staudinger reaction, using triphenylphosphine in a 
THF/H2O solvent mixture. The reduction proceeded cleanly to yield the primary amines 17-
20, as racemic mixtures. 	  
 	  	   	   	   	   	   Scheme 3 	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The final step in the synthesis of [Gd.L1-6] involved amide bond formation with the carboxylic 
acid of a DO3A-glutarate derivative (Scheme 3).15 This step was undertaken using 
EDC/HOBt for the formation of the active ester in the presence of NMM to deprotonate the 
primary amine. For the phosphonate series, removal of the ethyl ester groups was undertaken 
using TMS-Br in DMF. Complexation with GdCl3 proceeded cleanly at pH 6, and the 
complexes were purified by RP-HPLC following treatment with Chelex resin to remove any 
excess Gd salts.  The overall isolated yields were rather low (20-30%), and gave the 
paramagnetic complexes as a mixture of diasteroisomers in each case.  
	  
 	   	   	   	   	   Scheme 4 
 
The synthesis of the biotin conjugate, [Gd.L7] proceed via a similar reaction sequence 
(Scheme 4).  Z-Deprotection of the differentially protected penta-ester, 23, 15 followed be 
reaction with succinic anhydride in DMF afforded the monocarboxylic acid, 24. Following 
amide coupling (EDC, HOBt, NMM) to the antagonist derivative, 19, hydrolysis of the 
methyl ester in dilute base enabled coupling of the resultant carboxylic acid with an 
ethylenediamine derivative of biotin. Stepwise deprotection of the Boc and phosphinate ethyl 
groups gave the ligand L7 and complexation with GdCl3 proceeded well at pH 6 to afford 
[Gd.L7]. This complex could be used in confocal microscopy experiments in the presence of a 
fluorescently labeled avidin host molecule, in order to verify cell surface binding to the 
NMDA receptors of NSC-34 cells.  
 
Relaxivity properties and cell suspension MRI studies 
 
The longitudinal proton relaxivities of the seven Gd complexes were measured in water at 1.4 
T and 310 K, and the values fell in the expected range for such mono-aqua complexes of MW 
850 to 1450, for which the relaxivity value increases with molecular volume, as it scales with 
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the overall rotational correlation time. Values were also measured in the presence of human 
serum albumin (Table 1).   
Table 1.   Estimated binding affinities for serum albumin, a,b,c,d and relaxation properties of 
the      Gd complexes (310 K, pH 7.4, 1.4 T). 
 [Gd.L1] [Gd.L2] [Gd.L3]  [Gd.L4] [Gd.L5] [Gd.L6] 
log K a 2.2 1.9 3.7 1.6 1.6 3.7 
r1pinitial/mM-1 s-1  c 4.91 4.54 5.76 5.21 4.97 5.18 
r1plimit/ mM-1 s-1  c 
r1p/mM-1 s-1  b 
(at 0.7 mM HSA) 
18.0 
5.99 
22.0 
5.42 
7.50 
6.63 
30.0 
5.89 
25.0 
5.51 
8.50 
6.82 
 
a errors in logK values associated with experimental variation and statistical fitting were estimated to 
be  ± 0.1. The binding constants were estimated assuming a 1:1 stoichiometry; the relative affinity 
constant (IC50 value) for a structurally similar NMDA binding moiety (the anionic alcohol analogue of 
the phosphinate) was reported to be 19 nM, determined by a radiolabelled competition assay 11b; b 
statistical errors associated with the measurement of r1p values are ±0.03; c the r1plimit  and r1pinitial values 
were derived from the iterative least-squares fitting analysis; values for the complexes of L4 and L5 are 
subject to the largest error. d for [Gd.L7]2-, the relaxivity value in water was 7.23 mM-1s-1 (310 K, 60 
MHz) 
 
Human serum albumin (HSA) constitutes around 4.5% of plasma and is the major protein 
constituent in the circulatory system. Each contrast agent will bind to the protein to some 
extent, disrupting its rotational dynamics and leading to an enhancement of the longitudinal 
relaxation rate of the water protons. As a control experiment, the effect of added HSA on the 
measured relaxivity of [Gd.L1-6] (each at 1 mM) was assessed at 1.4 T following incremental 
addition of up to 1.6 mM HSA. Increases in r1p were observed and association constants were 
estimated by assuming a 1:1 stoichiometry of interaction. No particular trend was evident, 
correlating logK values with structure; indeed the weakest interaction occurred with the 
phosphonates, [Gd.L4]2- and [GdL5]2- , whilst the analogues with one less, [Gd.L3]2-,  and one 
more methylene groups, [Gd.L6]2-, bound to albumin 100 times more strongly in each case. At 
a protein concentration of 0.7 mM, the highest relaxivity values were measured for [Gd.L3]2- 
and [Gd.L6]2-, consistent with their higher binding affinities.  
A neuronal cell line model that expresses functional NMDA receptors had been 
established earlier using the NSC-34 cell line, produced by fusing mouse spinal cord 
and neuroblastoma cells. The cell line has been used in several studies of the 
evaluation of NMDAR antagonists.18 The expression of functional NMDA receptors 
on differentiated NSC-34 cells was demonstrated as reported earlier using immuno-
fluorescence techniques with primary antibodies. 13  The labelling of differentiated 
NSC-34 cells with [Gd.L1-6] was assessed by measuring the longitudinal relaxation 
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times, T1, of the water signal in cell suspensions using a Siemens human whole body 
MR scanner, equipped with a head coil operating at 3 T. These measurements allowed 
the calculation of cellular relaxation rates, R1,cell. Differentiated cells were incubated 
for 45 min with 200 µM [Gd.L1-6] (37 °C, 5% CO2), washed with Hank’s Buffered 
Saline Solution (HBSS) to remove unbound complex, re-suspended in fresh buffer and 
R1 was determined in cell suspensions using an inversion recovery sequence (Fig. 1). 
Values for R2 were also measured.
 
Figure 1      Cellular 1H MR relaxation rates, (a) R1,cell  and (b) R2,cell  in cell suspensions (3 T, 
298 K) after treatment of differentiated NSC-34 cells with 200 µM [Gd.DOTA]- or [Gd.L1-6] 
for 45 minutes. Under the same conditions, the Gd3+ complexes of La-Ld gave corresponding 
changes of +18, +70, -9 and +76% respectively.13 [Gd.DOTA]- served as a negative control. 
Values are mean ± SEM (n=4-8). *P<0.05, **P<0.01, ***P<0.001 statistical significant 
difference vs. untreated control; a P<0.001 statistical significant difference vs. [Gd.DOTA]- 
(ANOVA with Dunnett’s multiple comparison post test, assessed using Graphpad Prism 5.04). 
 
 
 
The largest enhancements in relaxation were evident with [Gd.L5]2- for which the 
enhancement was 19% in R1 and 37.5% in R2 over the untreated control and [Gd.DOTA]- 
treated cells. Moreover, this was one of the complexes exhibiting the weakest binding to 
serum albumin (Table 1). Given that albumin binding may be considered as a model for ‘non-
specific’ binding to a protein, such behaviour is encouraging. The much lower R1,cell value for 
[Gd.L6]2-, notwithstanding the addition of only a single methylene group to the targeting 
moiety, accords with the lower receptor affinity of such antagonists in earlier work 11b. The 
set of complexes [Gd.L1-4] each gave less than 6 to 12 % enhancements in R1 and R2 
respectively, suggesting that the receptor binding moiety may be too close to the bulky Gd 
complex, leading to inhibition of probe binding to the cell surface receptor, or that local 
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hydration or water exchange dynamics are compromised for the receptor bound complex in 
these cases (vide infra).    
 
The IC50 values of the gadolinium complexes [Gd.L1-6] were assessed using an MTT assay 
that probes the perturbation of mitochondrial redox activity of the differentiated NSC-34 
cells.19 Following a 24-hour incubation, each complex exhibited no cytotoxic effect at 
concentrations of up to 200 µM (data not shown), consistent with the hypothesis that the 
anionic probes were not being internalized into the cell. This hypothesis was corroborated by 
measuring the Gd cell uptake using ICP-MS. After a 24h incubation, followed by washing of 
the cells with fresh buffer three times, less than 2% Gd3+ cell uptake was measured in each 
case, and the gadolinium was found in the washings (ca. 98%).   
 
Cellular optical imaging 
It was hypothesised that the observed increase in relaxation rates per cell were due to 
binding of the Gd probe to NMDA receptors on the cell surface. However, cell 
labelling of the Gd complex via non-specific binding to the cell membrane or by 
internalisation involving receptor-mediated endocytosis are plausible mechanisms that 
may lead to the observed increase in R1,cell.  To distinguish these possibilities, the 
biotin complex was designed to allow tracking of the contrast agent on the cell surface.  
 
By attaching a fluorescent label to a non-competitive antagonist, the direct 
visualisation of the NMDAR-2B subunit has been demonstrated recently.20 
Accordingly, [Gd.L7] was designed, bearing the antagonist binding moiety of [Gd.L5], 
as this probe had shown the largest increase in R1,cell values. The complex includes a 
remote trans-substituted biotin sub-unit, attached to the macrocyclic core. It was 
hypothesised that if cell-surface receptor binding is responsible for the increase in 
R1,cell for [Gd.L5], the biotin moiety of [Gd.L7], after forming a tightly bound complex 
to added AvidinAlexaFluor® 488 conjugate, would be tagged to the outside of the cell. 
The presence of the fluorescent dye on the avidin sub-unit allows direct visualisation 
of the biotin complex using fluorescence microscopy, only when bound to the cell 
surface.  
In order to study the behaviour and localisation of [Gd.L7], laser scanning confocal 
microscopy (LSCM) imaging studies were carried out using live cells. The 
differentiated NSC-34 cells were grown on a microscope slide with a flow-through 
channel and were subjected to various different experimental conditions. Following 
incubation of the cells with a solution of [Gd.L7] (10 µM) and AvidinAlexaFluor® 
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488 conjugate (2.5 µM, 10 min) together, the cells were examined by microscopy and 
a localization profile was observed resembling ‘pit-like’ regions at the cell surface 
(Fig. 2A). The dye CellMask™ Orange is commercially available and can be used to 
stain the cell plasma membrane non-specifically. By repeating the simultaneous 
loading experiment of [Gd.L7] and AvidinAlexaFluor® 488 conjugate (10 min) and 
co-incubating with CellMask™ Orange (5 min, 5 µg/mL), unequivocal evidence for the 
selective localisation of [Gd.L7] at the cell membrane was obtained (Fig. 2B/2C). 
Furthermore, by using the same microscope settings as used previously,13 it was 
possible to demonstrate that cells treated with [Gd.L7] were 38% brighter than when 
they were treated with the acyclic analogue, consistent with the bicyclic targeting 
moiety having a higher receptor affinity. 
Confirmation that the observed fluorescence was due to the strong biotin-avidin 
interaction between [Gd.L7] and AvidinAlexaFluor® 488 conjugate on the cell surface 
was given through various control experiments. Differentiated cells loaded with 
AvidinAlexaFluor® 488 conjugate only and differentiated but untreated NSC-34 cells 
each gave rise to no fluorescence signal in the visible region, using the same 
experimental parameters as above. Cell surface localisation did not vary for stepwise 
vs. simultaneous incubations of the biotin and avidin moieties and was independent of 
time (5 to 45 minutes) and the loading concentration (up to 100 µM). No staining was 
observed with NIH-3T3 cells (mouse skin fibroblasts) that do not possess the NMDA 
receptors at the cell surface. In each of these control experiments, no evidence for any 
significant intracellular staining was observed.  
 
OBC	  	  2014	  	  
	   11	  
Figure 2. Live cell laser scanning confocal microscopy (LSCM) images of differentiated NSC-34 
cells following treatment with [Gd.L7].  
(A) Simultaneous loading of [Gd.L7] (10 µM), and AvidinAlexaFluor® 488 conjugate (2.5 µM, 10 
min) allowing visualisation of AvidinAlexaFluor® 488 conjugate λex/λem =488/505-555 nm.  
(B) As in (A), but with a 5 minute incubation of the non-specific cell-surface membrane dye 
CellMask™ Orange, allowing visualisation of CellMask™ Orange λex/λem = 543/550-660 nm.  (C) 
RGB merge showing co-localisation of the AvidinAlexaFluor® 488 conjugate and CellMask™ Orange 
on the cell surface.  
(D) As in image (A) but with a post glutamate (1mM) wash showing that [Gd.L7] is removed from the 
cell surface.  (E) As image (D) and then simultaneous loading of [Gd.L7] (10 µM), and 
AvidinAlexaFluor® 488 conjugate (2.5 µM, 45 min) allows 98% recovery of the fluorescence signal 
intensity as compared to image (A). (F) Loading of the antagonist, 27, (10 µM, 10 min) followed by 
simultaneous loading of [Gd.L7] (10 µM), and AvidinAlexaFluor® 488 conjugate (2.5 µM, 10 min).  
(G) Loading of 27 (10 µM, 10 min), followed by a glutamate wash (1 mM ) and then simultaneous 
loading of [Gd.L7] (10 µM), and AvidinAlexaFluor® 488 conjugate (2.5 µM, 45 min). (H) 
Simultaneous loading of [Gd.L7] (10 µM), AvidinAlexaFluor® 488 conjugate (2.5 µM) and [Gd.L3] 
(10 µM, 10 min). (I) Simultaneous loading of [Gd.L7] (10 µM), AvidinAlexaFluor® 488 conjugate 
(2.5 µM) and [Gd.L5] (10 µM, 10 min). See also the data given in Table 2.  
  
Competition experiments and reversibility of receptor binding 
OBC	  	  2014	  	  
	   12	  
The reversibility of [Gd.L7] receptor binding was demonstrated using a glutamate 
competition experiment. Differentiated NSC-34 cells were incubated with a solution of 
[Gd.L7] (10 µM) and AvidinAlexaFluor® 488 conjugate (2.5 µM, 10 min). After 
washing the cells with five successive aliquots (Vtot= 500 µL) of culture medium that 
was enriched in glutamate (1 mM), a nine-fold drop in fluorescence intensity was 
observed, compared to the original cell staining experiment (Fig. 2D). The ability of 
the probe to displace glutamate was also demonstrated. When differentiated NSC-34 
cells were sequentially treated the avidin/biotin components and with five volumetric 
aliquots of a glutamate rich (1 mM) culture medium, then washed with normal culture 
media and finally incubated with a solution of [Gd.L7] (10 µM) and 
AvidinAlexaFluor® 488 conjugate (2.5 µM, 10 min), 38% of signal was observed 
after 10 minutes and 98% of the original fluorescence signal intensity was recovered 
after 45 minutes (Fig. 2E). Such behaviour established the ability of the probe [Gd.L7] 
to displace glutamate from the NMDA receptor-binding site, as may occurred after a 
glutamate burst during neural signalling.  
 
In summary, these results show that [Gd.L7] is able to bind to the cell surface 
glutamate-binding site of the NMDAR, via the antagonist entity. 	  
	   	   	   	   	   	  	  
Table 2  Changes in the observed fluorescence intensity of [Gd.L7]-Avidin-             
  Alexa-488 conjugate (2.5 µM), under various conditions. 
  
[Gd.L7]a 
[Gd.L7]a, 
post Glu 
washb 
[Gd.L7]a, 
 Glu washb,  
[Gd.L7]a 
(10/45 mins) 
 
Antagonist, 
27c, 
[Gd.L7]a 
Antagonist 
27c, 
Glu washb, 
[Gd.L7]a 
[Gd.L7]a 
and 
[Gd.L3]d 
(1:1) 
[Gd.L7]a 
and 
[Gd.L5]d 
(1:1) 
Relative 
Fluorescence 
Intensity /% 
 
100 
 
11 
 
38/98 
 
<7 
 
18 
 
43 
 
56 
a Concentration of [Gd.L7] was 10 µM; b concentration of added glutamate in the medium was 1 mM; c 
concentration  of  the antagonist 27,  was 10 µM in each case; d concentration of [Gd.L3/5] = 10 µM. 
 
 
The competitive antagonist, 27, was synthesized in accordance with the methods of 
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Kinney, and has been shown to bind to the NMDA receptor with an affinity of the order of 20 
nM. 11b Co-incubation of 27 (10 µM) with [Gd.L7]2- and the Alexa-Fluor avidin conjugate 
gave rise to <7% of signal  intensity (Fig. 2F vs Fig. 2A).  By carrying out the following 
incubation sequence sequentially, first 27, then a Glu wash and finally incubation with 
[Gd.L7]2-, the observed signal grew to 18% . Evidently, the small molecule has a higher 
affinity for the NMDA receptor than the Gd probe, [Gd.L7]2-, but the restoration of some 
observed signal (18%) after the glutamate wash  (Fig. 2G) suggests that it may be important 
not to have a probe that is bound too tightly, or glutamate may not compete for receptor 
binding.  
Finally, competition experiments with equal concentrations of the parent complexes, 
[Gd.L3/5]2-  and [Gd.L7]2-  were undertaken (Table 2 and Fig. 2H and I), and the observation of 
about 50% of the original signal in each case is consistent with each of these complexes 
having a similar binding affinity for the NMDA receptor site.  
 
Conclusions 
A second generation of MR imaging probes has been created that target the NMDAR, 
based on a competitive antagonist approach. Of the series of six probes examined, 
[Gd.L5], showed a 19%, increase in the measured water proton relaxation rate in the 
presence of functional NMDARs on differentiated NSC-34 cells. Cell-surface 
localisation was demonstrated using confocal microscopy for the biotin-functionalised 
derivative, [Gd.L7]. No evidence was found for probe internalisation during the time-
periods used, neither was any evidence found for cell-surface binding, following probe 
incubation with an NMDA receptor negative cell-line, consistent with the inherent 
specificity of this approach.   
Binding of the Gd contrast agents to the NMDA receptors was shown to be reversible. 
Following addition of glutamate to the receptor-bound conjugate [Gd.L7], 
displacement of the complex from the receptors occurred, leading to a reduction of 
signal intensity in microscopy, that could be partially recovered by subsequent 
incubation with [Gd.L7] and the AvidinAlexaFluor® 488 conjugate.  
 
These in vitro and in cellulo studies suggest that such probes could be used in MRI 
studies in vivo, when the probes are injected intra-cranially to maintain a steady state 
local concentration, that may allow time-dependent modulation of glutamate   
concentration to be observed.  
 
Experimental 
OBC	  	  2014	  	  
	   14	  
Materials and Methods 
All solvents used were laboratory grade and anhydrous solvents, when required, were freshly 
distilled over the appropriate drying agent. Water was purified by the ‘PuriteSTILLplus’ 
system, with conductivity of ≤ 4 µS cm-1. All reagents used were purchased from commercial 
suppliers (Acros, Aldrich, Fluka, Merck and Strem) and were used without further 
purification unless otherwise stated. Reactions requiring anhydrous conditions were carried 
out using Schlenk line techniques under an atmosphere of argon.  
Thin layer chromatography was performed on neutral aluminium sheet silica gel plates 
(Merck Art 5554) and visualised under UV irradiation (254 nm), or using Dragendorff 
reagent staining. Preparative column chromatography was performed using silica gel (Merck 
Silica Gel 60, 230-400 mesh).  
Reverse phase HPLC was conducted at 298 K using a Shimadzu system. XBridge C18 4.6 x 
100 mm, i.d. 5 µm analytical column and XBridge C18 OBD 19 x 100 mm, i.d. 5 µm 
preparative columns were used to analyse and purify the complexes. A gradient elution with a 
solvent system composed of H2O + 0.1% HCOOH/MeOH + 0.1% HCOOH was performed 
for a total run time of 20.0 min.  
1H, 13C and 31P NMR spectra were recorded in commercially available deuterated solvents on 
a Varian Mercury-400 (1H 399.960, 13C 100.572), Bruker Avance-400 (1H 400.052, 13C 
100.603 and 31P 161.91), Varian Inova-500 (1H 499.722, 13C 125.671,), Appleby VNMRS-
600 (1H 599.832, 13C  150.828), or Varian VNMRA-700 (1H 699.731, 13C  175.948 and 31P 
283.26) spectrometer. All chemical shifts are given in ppm with coupling constants in Hz.  
Low resolution electrospray mass spectra (LR-MS) were recorded on a Fisons VG Platform 
II, Waters Micromass LCT or Thermo-Finnigan LTQ FT instrument operating in positive or 
negative ion mode as stated, with MeOH as the carrier solvent. Accurate mass spectra [High 
resolution electrospray mass spectra (HR-MS)] were recorded using the Thermo-Finnigan 
LTQ FT mass spectrometer.  
Melting points were recorded using a Gallenkamp (Sanyo) apparatus and are uncorrected.  
Relaxivity measurements were carried out at 310 K, 60 MHz (1.4 T) on a Bruker Minispec 
mq60 instrument. The mean value of three independent measurements was recorded. The 
relaxivities of the compounds were calculated as the slope of the function shown in the 
equation below,  
  
  
 
where T1,obs is the measured T1, T1,d is the diamagnetic contribution of the solvent (calculated 
to be 4000 ms) and [Gd.Ln] is the concentration in mM of the appropriate Gd3+ complex (n = 
1 - 6). Errors for all relaxivity values were less than 0.3 mM-1s-1.  
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The apparent binding constant for the interaction of the Gd3+ complex with Human Serum 
Albumin (HSA) was calculated using equation (2) below:  
where [X] is the total concentration of HSA in the solution; [Gd.Ln]: the total concentration of 
the complex; K: the binding constant; R: relaxation rate of a given concentration of X; R0: the 
initial relaxation rate; R1: final relaxation rate; [Gd.X]: the concentration of the HSA- 
coordinated complex; [Xf]: the concentration of free HSA in the mixture; [Gdf]: the 
concentration of the free complex. 
 
Details of cell experiments, microscopy, and the MTT assays used have been given in earlier 
papers in this series. 7-9,13 The other compounds, ligands and Gd complexes not reported 
below are described in the ESI.  
 
Ligand and Complex synthesis 
(3-Amino-2-hydroxypropyl)carbamic acid 1,1-dimethylethyl ester11b , 1 
 
 
 
A solution of 1,3-diamino-2-hydroxypropane (5.0 g, 55.5 mmol) in anhydrous acetonitrile (50 
mL) was maintained at room temperature and treated with a solution of di-tert-butyl 
dicarbonate (4.04 g, 18.5 mmol) in anhydrous acetonitrile (20 mL) over a 2-hour period with 
vigorous stirring. The subsequent suspension was left to stir overnight. After a period of 18 
hours, the reaction mixture was concentrated and the residue re-dissolved in brine (50 mL).  
The pH was adjusted to 5 by treatment with HCl (1 N), washed with dichloromethane (3 x 50 
mL) and made basic (pH 12) by the addition of NaOH solution (2.5 M). The product was 
extracted using copious amounts of CHCl3 (5 x 100 mL), dried over MgSO4, filtered and 
concentrated to yield 1 as a white solid (1.23 g, 34%).  1H NMR (400 MHz, CDCl3) δ 1.43 
(9H, s, C(CH3)3), 2.42-2.72 (3H, br, m), 2.78-2.92 (2H, br, m), 3.01-3.15 (1H, br, m), 3.20-
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3.35 (1H, br, m), 3.56-3.72 (1H, br, m), 5.05 (1H, br, s). 13C NMR (125 MHz, CDCl3) δ 28.4 
(C(CH3)3), 44.1, 44.5 (CH2), 71.0 (COH), 79.5 (C(CH3)3), 156.7 (CO). MS (ES+) m/z 191.1 
[M + H]+; C8H19N2O3 requires 191.1396; found 191.1392. M. Pt. 78-80 °C [lit.11b 77-79 °C]. 
 
Benzyl tert-butyl(2-hydroxypropane-1,3-diyl)dicarbamate, 2 	  14a  
 
 
 
To a solution of (3-amino-2-hydroxypropyl)carbamic acid 1,1-dimethylethyl ester (1.28 g, 
6.72 mmol) in anhydrous dichloromethane (43 mL) was added benzyl chloroformate (1.05 
mL, 7.39 mmol) and diisopropylethylamine (1.29 mL, 7.39 mmol) at 0 °C. The resulting 
solution was stirred under argon at this temperature for 30 mins before being allowed to warm 
to room temperature and stirred overnight. After complete consumption of starting materials 
has been revealed by TLC, the reaction mixture was concentrated and the crude residue 
purified by column chromatography (DCM/MeOH, 100% to 95:5 using 1% increments Rf = 
0.26) to give a pale green oil (1.64 g, 75%). 1H NMR (400 MHz, CDCl3) δ 1.43 (9H, s, 
C(CH3)3), 3.06-3.35 (4H, m, CH2), 3.76 (1H, quint, J = 6, CH), 5.09 (2H, s, CH2Ph), 5.14 
(1H, br, OH), 5.49 (2H, br, NH), 7.29-7.38 (5H, m, Ar-H). 13C NMR (101 MHz, CDCl3) δ 
28.5 (C(CH3)3), 43.7, 44.1 (CH2), 67.1 (CH2Ph), 70.9 (COH), 80.1 (C(CH3)3), 128.2, 128.3, 
128.7, 136.5 (Ar-C), 157.4, 157.6 (CO). MS (ES+) m/z 347.2 [M+Na]+; C16H24N2O5Na 
requires 347.1583; found 347.1593. 
 
11,11-Dimethyl-3,9-dioxo-1-phenyl-2,10-dioxa-4,8-diazadodecan-6-yl methylsulfonate 
 
 
Benzyl tert-butyl(2-hydroxypropane-1,3-diyl)dicarbamate (907 mg, 2.80 mmol) was 
dissolved in anhydrous dichloromethane (16 mL), to which triethylamine (430 µL, 3.08 
mmol) and methanesulfonyl chloride (238 µL, 3.08 mmol) were added at 0 °C. The resulting 
solution was stirred at this temperature for 5 minutes before being warmed to room 
temperature for a further 1 hour until complete conversion of the starting material was 
observed by ESI-MS. The solvent was removed under reduced pressure and the residue 
partitioned between brine and DCM (30 mL, 1:1). The organic portion was separated and the 
aqueous layer extracted with dichloromethane (3 x 30 mL). The combined organic portions 
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were dried over MgSO4, filtered and reduced to give a colourless oil which was used directly 
in the next step without further purification (1.20 g, 100%). 1H NMR (400 MHz, CDCl3) δ 
1.43 (9H, s, C(CH3)3), 3.04 (3H, s, CH3), 3.22-3.59 (4H, m, CH2), 4.68 (1H, br, NH), 5.10 
(2H, s, CH2Ph), 5.13 (1H, m, CH), 5.55 (1H, br, NH), 7.31-7.38 (5H, m, Ar-H). MS (ES+) 
m/z 403.1 [M+H]+. 
 
Benzyl tert-butyl (2-azidopropane-1,3-diyl)dicarbamate, 3 
 
 
 
To a solution of the mesylate (1.20 g, 2.93 mmol) in anhydrous dimethylformamide (13 mL) 
was added NaN3 (580 mg, 8.93 mmol) at room temperature. After addition, the cloudy 
mixture was heated to 60 °C under a stream of argon for 20 hours. Once no further conversion 
of starting materials has been revealed by ESI-MS, the mixture was cooled and the solvent 
removed under reduced pressure. The residue was partitioned between EtOAc/H2O (40 mL, 
1:1) and the organic portion separated. The aqueous was extracted with EtOAc (3 x 40 mL) 
and the combined organic portions dried over MgSO4, filtered, concentrated to give the crude 
residue which was purified by column chromatography (hexane/EtOAc, 90:10 to 70:30 using 
5% increments; Rf = 0.51) to give a colourless oil (605 mg, 59%). 1H NMR (400 MHz, 
CDCl3) δ 1.44 (9H, s, C(CH3)3), 3.07-3.28 (2H, m, CH2), 3.31-3.49 (2H, m, CH2), 3.66 (1H, 
quin, J = 6, CH), 5.04 (1H, br, NH), 5.11 (2H, s, CH2Ph), 5.46 (1H, br, NH), 7.28-7.39 (5H, 
m, Ar-H). 13C NMR (101 MHz, CDCl3) δ 28.4 (C(CH3)3), 40.9, 41.3 (CH2), 60.9 (CN3), 67.2 
(CH2Ph), 80.2 (C(CH3)3), 128.2, 128.4, 128.7, 136.4 (C-Ar), 156.4, 156.9 (CO). MS (ES+) 
m/z 372.1 [M+Na]+; C16H23N5O4Na requires 372.1648; found 372.1626. 
 
tert-Butyl (3-amino-2-azidopropyl)carbamate, 4 
 
 
 
Benzyl tert-butyl (2-azidopropane-1,3-diyl)dicarbamate (605 mg, 1.73 mmol) was dissolved 
in anhydrous glyme (40 mL) to which a solution of Ba(OH)2 in H2O (0.15 M, 20 mL) was 
added. The resulting solution was heated to 80 °C under argon, and the reaction progress 
monitored by ESI-MS and TLC. After 48 hours, the reaction was cooled to room temperature 
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and the solvent removed under reduced pressure. The residue was partially dissolved in brine 
and the pH adjusted to 5 using HCl (1 N).  The aqueous portion was washed with 
dichloromethane (2 x 100 mL) before adjusting the pH to 12 using NaOH solution (2.5 M). 
The product was extracted with copious amounts of CHCl3 (5 x 100 mL), dried over MgSO4, 
filtered and concentrated to give a colourless oil (257 mg, 69%). 1H NMR (400 MHz, CDCl3) 
δ 1.45 (9H, s, C(CH3)3), 1.56 (2H, bs. s), 2.76 (1H, dd, J = 13, 7, CHHNH), 2.88 (1H, dd, J = 
13, 5, CHHNH), 3.20 (1H, dt, J = 13, 7, CHHNH2), 3.35 (1H, dt, J = 13, 5 CHHNH2), 3.50-
3.60 (1H, m, CH), 4.89 (1H, br, NH). 13C NMR (101 MHz, CDCl3) δ 28.5 (C(CH3)3), 42.1, 
43.4 (CH2), 64.7 (CH), 78.4 (C(CH3)3), 156.6 (CO). MS (ES+) m/z 216.1 [M+H]+; C8H18N5O2 
requires 216.1461; found 216.1458. 
 
Methyl 3-((2-azido-3-((tert-butoxycarbonyl)amino)propyl)amino)propanoate, 6 
 
 
 
A solution of tert-butyl (3-amino-2-azidopropyl)carbamate (200 mg, 0.93 mmol), 
diisopropylethylamine (243 µL, 1.4 mmol) and methyl-3-bromopropionate (102 µL, 0.93 
mmol) in anhydrous DMF (8 mL) was stirred at room temperature for 48 hours until no 
further reaction was observed by TLC. The mixture was concentrated under reduced pressure 
before being partitioned between EtOAc/H2O (1:1, 30 mL). The organic portion was 
separated and the aqueous extracted with EtOAc (3 x 25 mL). The combined organic layer 
were dried over MgSO4, filtered and concentrated, allowing the crude residue to be purified 
by column chromatography (DCM/MeOH, 100% to 94:6 using 1% increments; Rf = 0.47) to 
give a pale yellow oil (220 mg, 79%). 1H NMR (400 MHz, CDCl3) δ 1.43 (9H, s, C(CH3)3), 
1.50 (1H, br, NH), 2.77 (2H, dd, J = 12, 7, CH2), 2.89 (2H, dd, J = 12, 5, CH2), 3.09 (2H, t, J 
= 6, CH2), 3.36 (2H, t, J = 6, CH2), 3.71 (3H, s, CH3), 4.02 (1H, m, CH),  5.19 (1H, br, NH). 
13C NMR (101 MHz, CDCl3) δ 28.4 (C(CH3)3), 32.5, 42.0, 44.8, 49.5 (CH2), 52.3 (CH3), 59.6 
(CN3), 80.4 (C(CH3)3), 156.5, 172.4 (CO). MS (ES+) m/z 302.2 [M+H]+; C12H24N5O4 requires 
302.1828; found 302.1831. 
 
Methyl 3-((2-azido-3-((tert-butoxycarbonyl)amino)propyl)(2-ethoxy-3,4-dioxocyclobut-1-
en-1-yl)amino)propanoate, 10 
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To a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (102 µL, 0.68 mmol) in anhydrous 
ethanol (1 mL), was added a solution of methyl 3-((2-azido-3-((tert-
butoxycarbonyl)amino)propyl)amino)propanoate (206 mg, 0.68 mmol) in anhydrous ethanol 
(5 mL) over 30 mins. The resulting solution was stirred under argon at room temperature and 
the progress of the reaction followed by TLC. When no further reaction was observed by 
TLC, the solution was concentrated under reduced pressure. The crude residue was then 
purified by column chromatography (DCM/MeOH, 100% to 95:5 using 0.5% increments; Rf 
= 0.59) to give a colourless oil, (234 mg, 81%). This compound exists as a pair of 
diasteroeisomers. 1H NMR (400 MHz, CDCl3) δ 1.41 (9H, s, C(CH3)3), 1.43 (3H, t, J = 7, 
OCH2CH3), 2.66 (2H, t, J = 7, CH2CH2CO2Me), 3.08-3.57 (3H, m, CH2), 3.66 (3H, s, CH3) 
3.71-4.07 (4H, m, CH2CH), 4.75 (2H, q, J = 7, OCH2CH3), 5.09 (1H, br, NH). 13C NMR (101 
MHz, CDCl3) δ 15.9 (OCH2CH3), 28.4 (C(CH3)3), 33.9, 42.2, 46.2, 51.1 (CH2), 52.1 (CH3), 
61.2 (CN3), 70.1 (OCH2CH3), 80.1 (C(CH3)3), 155.9 (CO), 171.2 (C=C) , 172.7 (CO), 177.4 
(C=C), 183.0, 188.4 (CO). MS (ES+) m/z 851.1 [2M+H]+; C36H55N10O14 requires 851.3899; 
found 851.3918. 
 
Methyl 3-(4-azido-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)propanoate, 14 
 
To a solution of methyl 3-((2-azido-3-((tert-butoxycarbonyl)amino)propyl)(2-ethoxy-3,4-
dioxocyclobut-1-en-1-yl)amino)propanoate (78 mg, 0.18 mmol) in anhydrous 
dichloromethane (1 mL) was added TFA (1 mL), and the resulting solution stirred at room 
temperature for 1 hour. Reaction was complete after this period, as indicated by TLC, and the 
solvents were removed under reduced pressure. The residue was re-dissolved in 
dichloromethane and again concentrated under reduced pressure. This process was repeated 5 
times to ensure complete removal of excess TFA. The TFA salt was dissolved in anhydrous 
ethanol (2 mL) to which a solution of triethylamine (102 µL, 0.736 mmol) in anhydrous 
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ethanol (1.5 mL) was added over a 20 minute period. The resulting solution was heated to 
reflux for 18 hours, until no further reaction was observed by TLC. At this point, the solvent 
was removed and the crude residue purified by column chromatography (DCM/MeOH, 100% 
to 90:10 using 1% increments; Rf = 0.52) to give a colourless oil (42 mg, 82%). 1H NMR (700 
MHz, DMSO-d6) δ 2.69 (2H, overlapping dt, J = 14, 7, CH2CO2Me), 3.40 (1H, dd, J = 14, 7, 
Ha(eq)), 3.55 (1H, ddd, J = 14, 7, 4, Ha(axial)), 3.57-3.59 (2H, br, m, Hc (ax/eq)), 3.60 (3H, s, 
CH3), 3.86 (1H, dt, J = 14, 7, CH2CH2CO2Me), 3.94 (1H, dt, J = 14, 7, CH2CH2CO2Me), 4.31 
(1H, m, CH), 8.53 (1H, br, NH). 13C NMR (176 MHz, DMSO-d6) δ 33.0 (Ce), 45.9 
(CH2CH2CO2Me), 47.5 (Ca), 51.5 (CH3), 54.4 (CH2CH2CO2Me), 58.9 (CN3), 167.7, 168.3 
(C=C), 171.1, 180.9, 181.0 (CO). MS (ES+) m/z 280.1 [M+H]+; C11H14N5O4 requires 
280.1046; found 280.1067. 
 
Methyl 3-(4-amino-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)propanoate, 18 
 
 
To a solution of methyl 3-(4-azido-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-
yl)propanoate (38 mg, 0.14 mmol) in anhydrous THF (3 mL) was added H2O (100 µL) and 
PPh3 (54 mg, 0.20 mmol). The suspension was stirred under argon at 60 °C and over time, 
became a clear solution. After stirring for 16 hours, the solvent was removed under reduced 
pressure and the crude residue partitioned between DCM and H2O (10 mL, 1:1). The aqueous 
layer was separated and washed twice with DCM (10 mL), before lyophilisation yielded a 
white solid (34 mg, 99%), m.p. > 250 °C. 1H NMR (700 MHz, DMSO-d6) δ 1.78-2.18 (2H, 
br, NH2), 2.69 (2H, overlapping dt, J = 14, 7, CH2CO2Me), 3.11 (2H, m, Ha), 3.21 (1H, dd, J 
= 14, 7, Hc(axial)), 3.27-3.31 (1H, m, Hb), 3.36 (1H, d, J = 14, Hc(eq)), 3.59 (3H, s, CH3), 
3.87 (1H, dt, J = 14, 7, CH2CH2CO2Me), 3.92 (1H, dt, J = 14, 7, CH2d’), 8.53 (1H, br, NH). 
13C NMR (176 MHz, DMSO-d6) δ 32.9 (CH2CH2CO2Me), 46.2 (CH2CH2CO2Me), 51.5 
(CH3), 51.6 (CH), 51.8 (CH2), 58.8 (CH2), 167.3, 168.0 (C=C), 171.3, 180.1, 181.2 (CO). 
MS (ES+) m/z 254.1 [M+H]+; C11H16N3O4 requires 254.1141; found 254.1166.   
 
tert-Butyl (2-azido-3-((3-(diethoxyphosphoryl)propyl)amino)propyl)carbamate, 8 
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A solution of tert-butyl (3-amino-2-azidopropyl)carbamate (395 mg, 1.84 mmol), sodium 
carbonate (293 mg, 2.76 mmol) and diethyl-3-bromopropyl phosphonate (560 µL, 2.91 
mmol) in anhydrous ethanol (8 mL) was boiled under reflux for 16 hours until no further 
reaction was observed by TLC. The mixture was concentrated under reduced pressure before 
being partitioned between DCM/H2O (1:1, 30 mL). The organic portion was separated and 
the aqueous extracted with dichloromethane (3 x 25 mL). The combined organic fractions 
were dried over MgSO4, filtered and concentrated, allowing the crude residue to be purified 
by column chromatography (DCM/MeOH, 100% to 92:8 using 1% increments; Rf = 0.35) to 
give the ester as a colourless oil (396 mg, 55%). 1H NMR (400 MHz, CDCl3) δ 1.31 (6H, t, J 
= 7, P(OCH2CH3)2), 1.43 (9H, s, C(CH3)3), 1.71-1.86 (5H, m, PCH2CH2CH2 + NH), 2.66 
(1H, dd, J = 12, 7, CHH), 2.69 (2H, m, PCH2CH2CH2), 2.71 (1H, dd, J = 12, 5, CHH), 3.17 
(1H, dt, J = 14, 7, CHH), 3.33 (1H, dt, J = 14, 5, CHH), 3.63-3.72 (1H, m, CH), 4.02-4.15 
(4H, qd, 3JH-H = 7, 3JH-P = 3, P(OCH2CH3)2), 5.01 (1H, br, NH). 13C NMR (101 MHz, CDCl3) 
δ 16.6 (d, 3J = 6, P(OCH2CH3)2), 23.0 (d, J = 5, NCH2CH2CH2P), 23.4 (d, 1J = 143, 
NHCH2CH2P), 28.5 (C(CH3)3), 42.6 (CH2), 50.0 (d, 2J = 18, NCH2CH2CH2P), 50.8 (CH2), 
61.7 (d, 2J = 7, P(OCH2CH3)2), 61.9 (CN3), 79.9 (C(CH3)3), 156.1 (CO). 31P NMR (CDCl3, 
162 MHz) δ 32.01. MS (ES+) m/z 394.2 [M+H]+; C15H32N5O5P requires 394.2219; found 
394.2215. 
 
tert-Butyl (2-azido-3-((3-(diethoxyphosphoryl)propyl)(2-ethoxy-3,4-dioxocyclobut-1-en-
1-yl)amino)propyl)carbamate, 12 
 
 
 
To a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (152 µL, 1.03 mmol) in anhydrous 
ethanol (1 mL), was added a solution of tert-butyl (2-azido-3-((3-
(diethoxyphosphoryl)propyl)amino)propyl)carbamate (396 mg, 1.0 mmol) in anhydrous 
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ethanol (7 mL) over 30 mins. The resulting solution was stirred under argon at room 
temperature and the progress of the reaction followed by TLC. After no further reaction was 
observed by TLC, the solution was concentrated under reduced pressure. The crude residue 
was then purified by column chromatography (DCM/MeOH, 100% to 95:5 using 0.5% 
increments; Rf = 0.44) to give a colourless oil, existing as a pair of rotamers (417 mg, 79%). 
1H NMR (700 MHz, CDCl3) δ 1.32 (6H, t, J = 7, P(OCH2CH3)2), 1.44 (9H, s, C(CH3)3), 1.46 
(3H, t, J = 7, OCH2CH3), 1.65-1.96 (4H, m, PCH2CH2CH2), 3.11-3.42 (2H, m, CH2), 3.48-
3.89 (5H, m, CH2CH + PCH2CH2CH2), 4.03-4.15 (4H, m, P(OCH2CH3)2), 4.75-4.80 (2H, m, 
OCH2CH3), 5.04 (1H, br, NH). 13C NMR (175 MHz, CDCl3) δ 16.0 (OCH2CH3), 16.6 (d, 3J = 
6, P(OCH2CH3)2), 22.3 (d, 2J = 5, NCH2CH2CH2P), 22.6 (d, 1J = 143, NCH2CH2CH2P), 28.4 
(C(CH3)3), 42.2 (CH2), 50.6 (d, 3J = 18, NCH2CH2CH2P), 50.8 (CH2), 61.1 (CN3), 62.0 (d, 2J 
= 7, P(OCH2CH3)2), 70.2 (OCH2CH3), 80.3 (C(CH3)3), 156.0 (CO), 172.7, 177.2 (C=C), 
182.9, 188.5 (CO). 31P NMR (CDCl3, 283 MHz) δ 30.14. MS (ES+) m/z 518.1 [M+H]+; 
C21H37N5O8P requires 518.2380; found 518.2375. 
 
Diethyl-3-(4-azido-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-
yl)propyl)phosphonate, 16 
 
To a solution of tert-butyl (2-azido-3-((3-(diethoxyphosphoryl)propyl)(2-ethoxy-3,4-
dioxocyclobut-1-en-1-yl)amino)propyl)carbamate (201 mg, 0.39 mmol) in anhydrous 
dichloromethane (1 mL) was added TFA (1 mL), and the resulting solution stirred at room 
temperature for 1 hour. Reaction was complete after this period, as indicated by TLC, and the 
solvents were removed under reduced pressure. The residue was re-dissolved in 
dichloromethane and again reduced under reduced pressure. This process was repeated 5 
times to ensure complete removal of excess TFA. The TFA salt was dissolved in anhydrous 
ethanol (5 mL) to which a solution of triethylamine (218 µL, 1.56 mmol) in anhydrous 
ethanol (2 mL) was added over a 20 minute period. The resulting solution was heated to 
reflux for 18 hours, until no further reaction was observed by TLC. At this point, the solvent 
was removed under reduced pressure and the crude residue purified by column 
chromatography (DCM/MeOH, 100% to 90:10 using 1% increments; Rf = 0.26) to give a 
colourless oil (126 mg, 87%). 1H NMR (400 MHz, CDCl3) δ 1.30 (6H, t, J = 7, 
P(OCH2CH3)2), 1.69-2.01 (4H, m, PCH2CH2CH2),  3.49 (1H, dd, J = 13, 7, Hc(axial)), 3.52-
3.62 (3H, m, Hc/a(eq), Ha(axial)), 3.71-4.11 (7H, m, CH + NCH2CH2CH2P + P(OCH2CH3)2), 
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8.16 (1H, br, s, NH). ). 13C NMR (101MHz, CDCl3) δ 16.5 (d, 3J = 6, P(OCH2CH3)2), 21.8 (d, 
2J = 5, NCH2CH2CH2P), 22.2 (d, 1J = 143, NCH2CH2CH2P), 48.5 (CH2), 51.3 (d, 3J = 18, 
NCH2CH2CH2P), 55.3 (CH2), 59.5 (CN3), 62.0 (d, 2J = 7, P(OCH2CH3)2), 167.6, 168.6 
(C=C), 180.9, 182.2 (CO). 31P NMR (CDCl3, 162 MHz) δ 30.80. MS (ES+) m/z 372.1 
[M+H]+; C14H23N5O5P requires 372.1437; found 372.1436. 
 
Diethyl-3-(4-amino-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-
yl)propyl)phosphonate, 20 
 
 
To a solution of diethyl (3-(4-azido-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-
yl)propyl)phosphonate (179 mg, 0.48 mmol) in anhydrous THF (10 mL) was added H2O (250 
µL) and PPh3 (189 mg, 0.72 mmol). The suspension was stirred under argon at 60 °C and 
over time, became a clear solution. After stirring for 16 hours, the solvent was removed under 
reduced pressure and the crude residue partitioned between DCM and H2O (20 mL, 1:1). The 
aqueous layer was separated and washed twice with DCM (10 mL), before lyophilisation 
yielded a white solid (155 mg, 94%), m.p. >250°C. 1H NMR (700 MHz, DMSO-d6) δ 1.23 
(6H, t, J = 7 P(OCH2CH3)2), 1.72-1.81 (4H, m, PCH2CH2CH2), 3.23-3.38 (2H, br, NH2), 
3.39-3.77 (7H, m, CH2 + CH), 3.95-4.01 (4H, qd, 3JH-H = 7, 3JH-P = 3, P(OCH2CH3)2), 8.57 
(1H, s, NH). 13C NMR (176 MHz, DMSO-d6) δ 16.3 (d, 3J = 6, P(OCH2CH3)2), 21.3 (d, 2J = 
5, NCH2CH2CH2P), 21.5 (d, 1J = 143, NCH2CH2CH2P), 47.9, 50.3 (CH),  50.7 (d, 3J = 18, 
NCH2CH2CH2P), 54.8 (CH2), 61.0 (d, 2J = 7, P(OCH2CH3)2), 167.9, 168.4 (C=C), 181.2, 
181.4 (CO). 31P NMR (162 MHz, DMSO-d6) δ 31.27. MS (ES+) m/z 346.1 [M+H]+; 
C14H25N3O5P requires 346.1532; found 346.1550. 
 
(R)-5-tert-Butoxy-5-oxo-4-[4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl]pentanoic acid	  15	  21 
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A solution of (R)-5-benzyl 1-tert-butyl 2-[4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl]pentanedioate3 (677 mg, 0.86 mmol) and Pd-C (10%) in MeOH 
(10 mL), was agitated at room temperature, under H2 (40 psi), in a Parr apparatus for 6 h. The 
reaction mixture was filtered through Celite and the filtrate evaporated under reduced 
pressure, to give the acid as a hygroscopic solid (530 mg, 88%). 1H NMR (400 MHz, CDCl3) 
δ 1.27 (9H, s, C(CH3)3), 1.28 (18H, s, C(CH3)3), 1.29 (9H, s, C(CH3)3), 1.86-2.16 (4H, m, 
CH2CH2CO), 2.18-3.18 (16H, br. m, CH2), 3.23 (4H, s, COCH2), 3.24 (2H, s, COCH2), 3.27-
3.35 (1H, m, COCH), 3.67 (1H, s, OH). 13C NMR (101 MHz, CDCl3) δ 27.6, 27.7, 27.9, 28.0 
(C(CH3)3), 33.7, 49.7, 52.5, 55.3, 55.6, 56.0, 60.1 (CH2), 69.6 (CH), 81.7, 82.0, 82.5 
(C(CH3)3), 171.2, 172.6, 175.2, 176.0 (CO). MS (ES+): m/z 701.1 [M+H]+; C35H65N4O10 
requires 701.4701; found 701.4704. 
 
(R)-4-((6-tert-Butoxy)-6-oxo-5-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)hexyl)amino)-4-oxobutanoic acid, 22 
 
 
To a pre-stirred solution of (R)-tri-tert-butyl 2,2’,2’’-(10-(6-amino-1-(tert-butoxy)-1-
oxohexan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate7 (325 mg, 0.46 mmol) 
and diisopropylethylamine (160 µL, 0.92 mmol) in anhydrous DMF (3 mL), was added 
succinic anhydride (46 mg, 0.46 mmol) and the resulting solution stirred at room temperature 
and the reaction monitored by ESI-MS. After 16 hours, the solvent was removed under 
reduced pressure and the crude residue purified by column chromatography (DCM/MeOH, 
100% DCM to 87:13; Rf = 0.32) to give a yellow gum (228 mg, 62%). 1H NMR (600 MHz, 
CDCl3) δ 1.34 (9H, s, C(CH3)3), 1.35 (18H, s, C(CH3)3), 1.36 (9H, s, C(CH3)3), 1.41-1.64 
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(6H, m), 1.96-2.06 (3H, m), 2.11-2.27 (4H, m), 2.37-2.54 (7H, m),  2.65-2.80 (6H, m), 2.83-
2.96 (3H, m), 3.10-3.20 (2H, m), 3.21-3.31 (3H, m), 3.32-3.33 (1H, m), 8.27-8.33 (1H, br. s, 
OH), 8.85 (1H, br.s, NH). 13C NMR (151 MHz, CDCl3) δ 24.5 (CH2), 26.5, 27.7, 27.8, 27.8 
(C(CH3)3), 28.8, 30.0, 31.8, 39.1, 44.5, 47.1, 48.0, 48.3, 48.4, 52.4, 52.5, 53.5, 55.4, 55.6, 
55.7 (CH2), 61.1 (CH), 81.9, 82.0, 82.0 (C(CH3)3), 172.5, 172.7, 174.4, 174.8, 175.1 (CO). 
MS (ES+) m/z 800.4 [M+H]+; C40H74N5O11 requires 800.5385; found 800.5366. 
 
 
 
[Conjugate 2] 
 
 
(R)-5-tert-Butoxy-5-oxo-4-[4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl]pentanoic acid (94 mg, 0.13 mmol), EDC (31 mg, 0.16 mmol) and 
HOBt (22 mg, 0.16 mmol) were dissolved in anhydrous DMF (2 mL) and stirred at room 
temperature under an atmosphere of argon for 20 minutes. After this period, a pre-stirred 
solution of methyl 3-(4-amino-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)propanoate 
(34 mg, 0.13 mmol) and NMM (30 µL, 0.27 mmol) in anhydrous DMF (1.5 mL) was added 
dropwise and the resulting solution stirred at room temperature until complete consumption of 
the starting materials was revealed by ESI-MS. After this period, the solvent was removed 
under reduced pressure and the crude oil taken up into EtOAc (20 mL). NaHCO3 (20 mL) was 
added, the layers separated and the aqueous fraction washed with EtOAc (3 x 40 mL). The 
combined organic portions were dried over MgSO4, filtered and the solvent removed under 
reduced pressure. The crude residue was purified by column chromatography (DCM/MeOH, 
100% to 90:10 in 1% increments; Rf = 0.37) to yield a pale brown viscous oil. This product 
was characterized as a pair of diastereoisomers (33 mg, 26%). 1H NMR (600 MHz, CDCl3) δ 
1.42-1.44 (36H, overlapping s, C(CH3)3), 1.82-1.93 (1H, m), 1.95-2.11 (4H, m), 2.17-2.27 
(3H, m), 2.34-2.41 (1H, m), 2.49-2.58 (4H, m), 2.60-2.70 (5H, m, CH2e + CH2), 2.71-2.78 
(2H, m), 2.78-2.85 (2H, m), 2.89-2.99 (3H, m),  3.29-3.38 (2H, m), 3.40-3.52 (4H, m, Ha + 
CH), 3.64 (3H, s, CH3), 3.77-3.87 (2H, m, Hc), 3.94 (1H, dt, J = 14, 7, CH2d), 4.03 (1H, dt, J 
= 14, 7, CH2d’), 4.13-4.19 (1H, m, CHNH), 7.72 (1H, br, NH), 8.70 (1H, br, NH). 13C NMR 
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(151 MHz, CDCl3) δ 27.9, 28.0 (overlapping C(CH3)3), 33.8 (Ce), 35.3, 45.6, 47.2 (Cd), 48.2, 
48.7, 49.8, 50.2 (CHNH), 51.2 (CH3), 52.8, 55.6, 55.9, 56.4, 60.8 (CH), 82.0, 82.1, 82.1, 82.2 
(C(CH3)3), 167.7, 167.9 (C=C), 171.4, 172.6, 172.8, 172.9, 173.5,  175.3, 181.2, 182.0 (CO). 
MS (ES+) m/z 936.6 [M+H]+; C46H78N7O13 requires 936.5658; found 936.5672. 
 
[Conjugate 4] 
 
(R)-5-tert-Butoxy-5-oxo-4-[4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl]pentanoic acid (138 mg, 0.20 mmol), EDC (45 mg, 0.24 mmol) 
and HOBt (32 mg, 0.24 mmol) were dissolved in anhydrous DMF (3 mL) and stirred at room 
temperature under an atmosphere of argon for 20 minutes. After this period, a pre-stirred 
solution of diethyl (3-(4-amino-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-
yl)propyl)phosphonate (68 mg, 0.20 mmol) and NMM (43 µL, 0.39 mmol) in anhydrous 
DMF (2 mL) was added dropwise and the resulting solution stirred at room temperature until 
complete consumption of the starting materials was revealed by ESI-MS. After this period, 
the solvent was removed under reduced pressure and the crude oil taken up into EtOAc (30 
mL). NaHCO3 (30 mL) was added, the layers separated and the aqueous washed with EtOAc 
(3 x 50 mL). The combined organic portions were dried over MgSO4, filtered and the solvent 
removed under reduced pressure. The crude residue was purified by column chromatography 
(DCM/MeOH, 100% to 90:10 in 1% increments; Rf =0.41) to yield a dark yellow viscous oil. 
This product was characterized as a pair of diastereoisomers (57 mg, 28%). 1H NMR (700 
MHz, CDCl3) δ 1.27 (6H, t, J = 7, P(OCH2CH3)2), 1.40, 1.40, 1.41, 1.42 (36H, s, C(CH3)3), 
1.66-1.74 (2H, m, PCH2CH2CH2), 1.81-1.89 (3H, m, PCH2CH2CH2 + CHH), 1.96-2.09 (4H, 
m), 2.15-2.23 (3H, m), 2.32-2.40 (1H, m), 2.45-2.56 (4H, m), 2.59-2.64 (3H, m), 2.70-2.76 
(2H, m), 2.76-2.82 (2H, m), 2.87-2.97 (3H, m), 3.28-3.35 (2H, m), 3.36-3.38 (1H, m), 3.40-
3.44 (1H, m), 3.46-3.54 (2H, m), 3.61-3.68 (1H, m), 3.72-3.77 (1H, m, Hc) 3.79-3.87 (2H, m, 
PCH2CH2CH2), 3.99-4.07 (4H, m, P(OCH2CH3)2), 4.13-4.19 (1H, m, Hb), 7.56 (1H, br, NH), 
8.85 (1H, br, NH). 13C NMR (176 MHz, CDCl3) δ 16.6 (d, 3J = 6, P(OCH2CH3)2), 22.0 (d, 2J 
= 5, NCH2CH2CH2P), 22.9 (d, 1J = 143, NCH2CH2CH2P), 27.9, 28.0 (overlapping C(CH3)3), 
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35.3, 38.7, 44.5, 47.1, 48.4, 50.2 (CHNH), 51.5 (d, 3J = 16, NCH2CH2CH2P), 52.8, 55.6, 55.9, 
56.2, 60.7 (CH), 61.7 (overlapping d, 2J = 7, P(OCH2CH3)2), 82.0, 82.1, 82.1, 82.3 (C(CH3)3), 
167.4, 167.8 (C=C), 172.6, 172.8, 172.9, 173.4, 175.3, 181.4, 181.8 (CO). 31P NMR (283 
MHz, CDCl3) δ 30.85. MS (ES+) m/z 1028.5 [M+H]+; C49H87N7O14P requires 1028.605; found 
1028.606. 
[Gd.L2] 
 
 
The [Conjugate 2] (10 mg, 0.01 mmol) was dissolved in MeOH (200 µL) with stirring. To 
this was added NaOH (0.5 mg) as a solution in H2O (2.5 M) and the resulting solution stirred 
at room temperature overnight. Complete removal of the methyl ester was verified by ESI-
MS, at which point the solvent was removed under reduced pressure. The residue was 
completely dried under high vacuum before being suspended in DCM (1 mL), to which 
trifluoroacetic acid (1 mL) was added. The resulting yellow solution was stirred at room 
temperature overnight. Complete removal of the tert-butyl ester groups was verified by ESI-
MS, at which point excess solvent was removed under reduced pressure. The residue was 
repeatedly re-dissolved in DCM (2 mL) and the solvent removed under reduced pressure to 
remove excess TFA. This process yielded the protonated salt of L2 as a pale-brown solid. MS 
(ES+) m/z 698.3 [M+H]+. The salt of L2 (7.5 mg, 0.01 mmol) was dissolved in H2O (0.5 mL) 
and the pH adjusted to about 5.5 by the addition of NaOH (0.1 M). GdCl3.6H2O (4.8 mg, 
0.013 mmol) was added as a solution in H2O (0.5 mL) and the reaction mixture stirred at 60 
°C overnight. The pH of the solution was periodically checked and maintained between 5-6 
with the addition of NaOH/HCl (0.1 M). Upon completion of complexation, excess 
gadolinium was removed by the addition of Chelex-100™ with stirring. The Chelex trap was 
filtered and the complex eluted with excess H2O. Removal of the water by lyophilisation gave 
a white solid that was purified by RP-HPLC. HR-MS (ES+) C29H41154GdN7O13 requires 
849.1971 [M+2H]+; found 849.1956. r1p = 4.54 mM-1s-1 (60 MHz, 310K). RP-HPLC: tR = 7.1 
mins [2-30% MeOH in H2O over 10 mins]. 
 
[Gd.L4] 
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[Conjugate 4] (17 mg, 0.02 mmol) was dissolved in DCM (1 mL) with stirring. To this 
solution was added trifluoroacetic acid (1 mL) and the resulting solution stirred at room 
temperature for overnight. Hydrolysis of the tert-butyl ester groups was verified by ESI-MS, 
at which point the excess solvent was removed under reduced pressure. The residue was 
repeatedly re-dissolved in DCM (2 mL) and the solvent removed under reduced pressure to 
remove excess TFA. This process yielded the phosphonate ethyl ester as a light-brown solid. 
This residue was dissolved in DMF (1 mL) to which bromotrimethylsilane (18 µL, 0.13 
mmol) was added dropwise. The resulting mixture was heated to 60 °C overnight until 
complete hydrolysis occurred as indicated by ESI-MS. The solvent was removed under 
reduced pressure, before the residue re-dissolved in H2O. The pH was adjusted to 6 and the 
aqueous phase washed with DCM (3 x 3 mL) and diethyl ether (3 x 3 mL). The aqueous 
solvent was then removed by lyophilisation to give the protonated salt of L4 as a light brown 
solid. MS (ES+) m/z 748.7 [M+H]+. The salt of L4 (12.5 mg, 0.017 mmol) was dissolved in 
H2O (0.5 mL) and the pH adjusted to 5.5. GdCl3.6H2O (6.8 mg, 0.018 mmol) was added as a 
solution in H2O (0.5 mL) and the reaction mixture stirred at 60 °C overnight. The pH of the 
solution was periodically checked and maintained between 5 and 6 with the addition of 
NaOH/HCl (0.1 M). Upon completion of complexation, excess gadolinium was removed by 
the addition of Chelex-100 with stirring. The Chelex trap was filtered and the complex 
eluted with excess H2O. Removal of the water by lyophilisation gave the complex, [Gd.L4] as 
a white solid that was purified by RP-HPLC. HR-MS (ES+) C29H44154GdN7O14P requires 
899.1893 [M+2H]+; found 899.1891. r1p = 5.21 mM-1s-1 (60 MHz, 310K). RP-HPLC: tR = 7.5 
mins [2-30% MeOH in H2O over 10 mins]. 
 
[Gd.L6] 
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[Conjugate 6] (10 mg, 0.01 mmol) was dissolved in DCM (1 mL) with stirring. To this 
solution was added trifluoroacetic acid (1 mL) and the resulting solution stirred at room 
temperature for overnight. Hydrolysis of the tert-butyl ester groups was verified by ESI-MS, 
at which point the excess solvent was removed under reduced pressure. The residue was 
repeatedly re-dissolved in DCM (2 mL) and the solvent removed under reduced pressure to 
remove excess TFA. This process yielded the phosphonate ethyl ester as a light-brown solid. 
This residue was dissolved in DMF (1 mL) to which bromotrimethylsilane (10 µL, 0.07 
mmol) was added dropwise. The resulting mixture was heated to 60 °C overnight until 
complete hydrolysis was indicated by ESI-MS. The solvent was removed under reduced 
pressure, before the residue re-dissolved in H2O. The pH was adjusted to 6 and the aqueous 
phase washed with DCM (3 x 3 mL) and diethyl ether (3 x 3 mL). The aqueous solvent was 
then removed by lyophilisation to give the protonated salt of L12 as a light brown solid. MS 
(ES+) m/z 847.8 [M+H]+. The salt of L12 (7.6 mg, 0.01 mmol) was dissolved in H2O (1 mL) 
and the pH adjusted to 6. GdCl3.6H2O (4.0 mg, 0.011 mmol) was added as a solution in H2O 
(0.5 mL) and the reaction mixture stirred at 60 °C overnight. The pH of the solution was 
periodically checked and maintained between 5 and 6 with the addition of NaOH/HCl (0.1 
M). Upon completion of complexation, excess gadolinium was removed by the addition of 
Chelex-100 with stirring. The Chelex trap was filtered and the complex eluted with excess 
H2O. Removal of the water by lyophilisation gave the complex as a white solid that was 
purified by RP-HPLC. HR-MS (ES+) C34H53158GdN8O15P requires 1002.261 [M+2H]+; found 
1002.267. r1p = 5.18 mM-1 s-1 (60 MHz, 310K). RP-HPLC: tR = 7.8 mins [2-30% MeOH in 
H2O over 10 mins]. 
Compound 26 
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(2R)-1-tert-Butyl 5-methyl 2-(4,10-bis(2-(tert-butoxy)-2-oxoethyl)-7-((2R)-1-(tert-butoxy)-6-
(4-((2-(2-(diethoxyphosphoryl)ethyl)-8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-4-
yl)amino)-4-oxobutanamido)-1-oxohexan-2-yl)-1,4,7,10-tetraazacyclododecan-1-
yl)pentanedioate (50 mg, 0.042 mmol) was dissolved in methanol (1 mL) and NaOH (2 mg, 
0.051 mmol) was added as a solution in H2O (250 µL). The light yellow solution was stirred 
at room temperature and progress of the reaction monitored by ESI-MS. Upon complete 
hydrolysis of the methyl ester after 1 hour, the solvent was removed under reduced pressure 
to give a pale yellow solid, which was dried fully on a high vacuum line. This yielded the 
carboxylic acid (49 mg, 0.042), to which EDC (9.6 mg, 0.050 mmol) and HOBt (6.8 mg, 
0.050 mmol) were added and dissolved in anhydrous DMF (1 mL). The mixture was stirred at 
room temperature under an atmosphere of argon for 20 minutes. After this period, a pre-
stirred solution of N-(2-Aminoethyl)-5-((3aS, 4S, 6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide16 (12 mg, 0.042 mmol) and NMM (9 µL, 0.083 mmol) in 
anhydrous DMF (0.5 mL) was added dropwise and the resulting solution stirred at room 
temperature until complete consumption of the starting materials was revealed by ESI-MS. 
After this period, the solvent was removed under reduced pressure and the crude oil taken up 
into EtOAc (15 mL). NaHCO3 (15 mL) was added, the layers separated and the aqueous 
washed with EtOAc (3 x 20 mL). The combined organic portions were dried over MgSO4, 
filtered and the solvent removed under reduced pressure. The crude residue was purified by 
column chromatography (DCM/MeOH/NH4OH, 100% to 80:15:5; Rf =0.15) to yield a yellow 
oil (10 mg, 17%). 1H NMR (700 MHz, CDCl3) δ 1.29-1.37 (6H, m, P(OCH2CH3)2), 1.40-1.51 
(40H, m), 1.56-1.75 (5H, m), 2.22-2.80 (20H, m), 2.80-3.51 (31H, m), 3.60-3.93 (5H, m), 
5.05-4.15 (4H, m, P(OCH2CH3)2), 4.21-4.52 (3H, m), 7.87-8.51 (3H, m). 31P NMR (283 
MHz, CDCl3) δ 27.17. MS (ES+) m/z 727.4 [M+2H]2+; C68H118N12O18PS requires 1453.815; 
found 1453.819. 
[Gd.L7] 
 
 
Compound 26 (10 mg, 0.007 mmol) was dissolved in DCM (1 mL) with stirring. To this 
solution was added trifluoroacetic acid (1 mL) and the resulting solution stirred at room 
temperature for overnight. Hydrolysis of the tert-butyl ester groups was verified by ESI-MS, 
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at which point the excess solvent was removed under reduced pressure. The residue was 
repeatedly re-dissolved in DCM (2 mL) and the solvent removed under reduced pressure to 
remove excess TFA. This process yielded the phosphonate ethyl ester as a light-brown solid. 
This residue was dissolved in DMF (0.8 mL) to which bromotrimethylsilane (7 µL, 0.055 
mmol) was added dropwise. The resulting mixture was heated to 60 °C overnight until 
complete hydrolysis as verified by ESI-MS. The solvent was removed under reduced 
pressure, before the residue re-dissolved in H2O. The pH was adjusted to 6 and the aqueous 
phase washed with DCM (3 x 2 mL) and diethyl ether (3 x 2 mL). The aqueous solvent was 
then removed by lyophilisation to give the protonated salt of L7 as a light brown solid. MS 
(ES+) m/z 587.0 [M+2H]2+. The salt of L7 (8.1 mg, 0.007 mmol) was dissolved in H2O (0.5 
mL) and the pH adjusted to 6. GdCl3.6H2O (3.1 mg, 0.008 mmol) was added as a solution in 
H2O (0.5 mL) and the reaction mixture stirred at 60 °C overnight. The pH of the solution was 
periodically checked and maintained between 5 and 6 with the addition of NaOH/HCl (0.1 
M). Upon completion of comlexation, excess gadolinium was removed by the addition of 
Chelex-100 with stirring. The Chelex trap was filtered and the complex eluted with excess 
H2O. Removal of the water by lyophilisation gave the complex  as a white solid that was 
purified by RP-HPLC. HR-MS (ES+) C48H75154GdN12O18PS requires 1324.399 [M+2H]+; 
found 1324.399. r1p = 7.23 mM-1 s-1 (60 MHz, 310K). RP-HPLC: tR = 16.7 mins [2-30% 
MeOH in H2O over 10 mins]. 
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